
    
      The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate of
      rapid (after the 4th week) and early (after the 12th week) virologic response will be based
      on polymerase chain reaction data. For patients with treatment failure after the 12th week
      the antiviral therapy shall be discontinued. All patients who require further anti-viral
      treatment will receive a combination treatment with Algeron / PegIntron and ribavirin for
      another 36 weeks. Sustained virologic response will be assessed 24 weeks after last dose of
      study treatment.
    
  